Arcutis Q3 net loss $107.7M ($1.89/share); ZORYVE launch generates $0.7M revenue

Arcutis Biotherapeutics, Inc.

2022-Q3 EPS reported -$4.52 revenue$725,000

Net product revenue of $0.7M from ZORYVE launch; about half from wholesaler inventory build.
Net loss $107.7M ($1.89 per share) vs $57.0M ($1.14) YoY; Ducentis acquisition added $0.51 per share.
R&D expenses $69.7M (incl. $30M Ducentis upfront); SG&A $35.5M on launch costs.
Cash, equivalents, and marketable securities $478.2M; $162M from Aug 2022 public offering and $125M debt draw.
Positive topline Phase 3 data for roflumilast foam in scalp/body psoriasis; enrollment completed in atopic dermatitis trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcutis Biotherapeutics, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) issued a press release relating to its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-22-000070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.